Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

/PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently...

Related Keywords

Guangzhou ,Guangdong ,China ,Chengdu ,Sichuan ,Jinan ,Shandong ,Shanghai ,United States ,Hong Kong ,Shenzhen ,Beijing ,Wuhan ,Hubei ,Nanjing ,Jiangsu ,Keymed Bio ,Biosciences Inc ,Keymed Biosciences Inc ,Team Of Talents Expanded Manufacturing Capabilities ,Prnewswire Keymed Biosciences Inc ,Hong Kong Stock Exchange On ,Differentiated Pipelines ,Initiated Phase ,Orphan Drug Designation ,Fast Track Designation ,Expanded Manufacturing ,Shenzhen Hong Kong Stock ,Small Cap Index ,Small Cap ,Stock Code ,Hong Kong Stock Exchange ,Keymed ,